These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19637334)

  • 1. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
    Reinisch W; de Villiers W; Bene L; Simon L; Rácz I; Katz S; Altorjay I; Feagan B; Riff D; Bernstein CN; Hommes D; Rutgeerts P; Cortot A; Gaspari M; Cheng M; Pearce T; Sands BE
    Inflamm Bowel Dis; 2010 Feb; 16(2):233-42. PubMed ID: 19637334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
    Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T
    Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
    Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
    Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Cohen A; Bitton A; Baker J; Dubé R; Landau SB; Vandervoort MK; Parikh A
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1370-7. PubMed ID: 18829392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
    Targan SR; Feagan B; Vermeire S; Panaccione R; Melmed GY; Landers C; Li D; Russell C; Newmark R; Zhang N; Chon Y; Hsu YH; Lin SL; Klekotka P
    Am J Gastroenterol; 2016 Nov; 111(11):1599-1607. PubMed ID: 27481309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
    Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
    J Gastroenterol; 2020 Mar; 55(3):291-306. PubMed ID: 31836930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
    Sandborn WJ; Rutgeerts P; Colombel JF; Ghosh S; Petryka R; Sands BE; Mitra P; Luo A
    J Crohns Colitis; 2017 Jul; 11(7):811-819. PubMed ID: 28333187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
    van der Woude CJ; Stokkers P; van Bodegraven AA; Van Assche G; Hebzda Z; Paradowski L; D'Haens G; Ghosh S; Feagan B; Rutgeerts P; Dijkstra G; de Jong DJ; Oldenburg B; Farhan M; Richard T; Dean Y; Hommes DW;
    Inflamm Bowel Dis; 2010 Oct; 16(10):1708-16. PubMed ID: 20848453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
    Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
    Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
    Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W
    Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
    Hueber W; Sands BE; Lewitzky S; Vandemeulebroecke M; Reinisch W; Higgins PD; Wehkamp J; Feagan BG; Yao MD; Karczewski M; Karczewski J; Pezous N; Bek S; Bruin G; Mellgard B; Berger C; Londei M; Bertolino AP; Tougas G; Travis SP;
    Gut; 2012 Dec; 61(12):1693-700. PubMed ID: 22595313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
    Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
    Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Feagan BG; Sandborn WJ; Lichtenstein G; Radford-Smith G; Patel J; Innes A
    Aliment Pharmacol Ther; 2006 Mar; 23(5):617-28. PubMed ID: 16480401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Sandborn WJ; Lee SD; Tarabar D; Louis E; Klopocka M; Klaus J; Reinisch W; Hébuterne X; Park DI; Schreiber S; Nayak S; Ahmad A; Banerjee A; Brown LS; Cataldi F; Gorelick KJ; Cheng JB; Hassan-Zahraee M; Clare R; D'Haens GR
    Gut; 2018 Oct; 67(10):1824-1835. PubMed ID: 28982740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.